Today's Highlights
Premium
Alkermes: Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
Alkermes in the NEWS Today, Alkermes Inc., ( ALKS ) announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 ( NT1 ). Alixorexton...
P
Prohost Biotech
1 min read
3
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Tags
Comments (0)
Please sign in to join the discussion